Caribou Biosciences, Inc.

Passed

Offering Date:
(a) common stock pursuant and/or traceable to documents issued in connection with the Company’s initial public offering conducted on or about July 23, 2021; and/or (b) securities between July 23, 2021, and December 9, 2022, both dates inclusive

Lead Plaintiff Deadline:
April 11, 2023

Case Form

Find Out if You Potentially Qualify for a Financial Reward by filling out the form.












The submission of this form does not create an attorney-client relationship.

Allegations

(i) the treatment effect of the Company's product candidate, CB-010, was not as durable as defendants had led investors to believe; (ii) accordingly, CB-010’s clinical and commercial prospects were overstated; and (iii) as a result, documents issued in connection with Caribou's initial public offer and defendants’ public statements throughout the class period were materially false and/or misleading and failed to state information required to be stated therein.

Eligibility

In order to be included in the lawsuit, you must have incurred a loss on shares of purchased or acquired during the class period listed above and/or pursuant to the stock offering(s) referenced above.

Lead Plaintiff Deadline

If you suffered a loss in during the relevant time frame or pursuant to the relevant offering(s), you have until April 11, 2023 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.